The U.S. Food and Drug Administration has approved a new mRNA-based seasonal flu vaccine for people 50 and older, Moderna said this week.

The approval of Moderna’s new flu vaccine comes months after the FDA faced backlash for refusing to review the shot.

The FDA has approved the nation’s first messenger RNA-based influenza vaccine, marking a significant development in the fight against the respiratory illness — and the end of a…

The vaccine, developed by Moderna, is approved for adults ages 50 to 64 and those 65 and older, who face the highest risk of severe illness.